Kancera reports start of patient screening for the KANDOVA-study

Kancera reports that patient screening for the KANDOVA-study has been initiated at the Karolinska University Hospital in Solna, Sweden, one of the university hospitals in Sweden, Denmark and Norway that are planned to be part of the study. Kancera further reports that the regulatory applications to conduct the KANDOVA-study have also been approved in Norway and Denmark. Kancera expects that patient screening at the other Nordic study sites will be initiated stepwise during the second quarter.

About the KANDOVA-study
The KANDOVA-study is a combined phase Ib/IIa study of KAND567 in combination with carboplatin therapy in ovarian cancer patients with relapsed disease. The study is conducted in collaboration with the clinical trials unit of the Nordic Society of Gynaecological Oncology (NSGO-CTU) and is planned to be conducted at the leading university hospitals in Sweden, Denmark and Norway. The primary objective is to evaluate safety and tolerability. The secondary objective is to evaluate evidence of KAND567 treatment efficacy. The long-term objective is to restore sensitivity to platinum treatment and thereby prolong survival. Top line results are expected to be reported during H2 2024.

About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information:
Peter Selin
Executive Vice President, Kancera AB
Tel: +46 (0)8-5012 6080

Visit Kancera’s web page: https://www.kancera.com/en